Detalhe da pesquisa
1.
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.
Gut
; 72(3): 581-589, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36750244
2.
Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat.
Clin Gastroenterol Hepatol
; 21(1): 143-152.e3, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34999207
3.
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.
Hepatology
; 75(5): 1235-1246, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34662449
4.
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
Hepatology
; 73(2): 625-643, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33169409
5.
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease.
Hepatology
; 69(2): 684-698, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30153359
6.
Effect of Renal Impairment on the Pharmacokinetics of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, and Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist.
J Clin Pharmacol
; 63(5): 560-568, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36700458
7.
Derivation and validation of the nonalcoholic fatty liver disease cirrhosis score (NCS) to distinguish bridging fibrosis from cirrhosis.
Eur J Intern Med
; 98: 53-60, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35058147